613 reports of this reaction
3.3% of all EFAVIRENZ reports
#6 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #6 most commonly reported adverse reaction for EFAVIRENZ, manufactured by Aurobindo Pharma Limited. There are 613 FDA adverse event reports linking EFAVIRENZ to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 3.3% of all 18,805 adverse event reports for this drug.
Patients taking EFAVIRENZ who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among EFAVIRENZ users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for EFAVIRENZ:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 613 FDA reports for EFAVIRENZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 3.3% of all adverse event reports for EFAVIRENZ, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking EFAVIRENZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.